Literature DB >> 26003555

Long-Term Administration of Fibroblast Growth Factor 21 Prevents Chemically-Induced Hepatocarcinogenesis in Mice.

Pengfei Xu1, Yingjie Zhang1, Wenfei Wang1, Qingyan Yuan1, Zhihang Liu1, Lubna Muhi Rasoul1,2, Qiang Wu1, Mingyao Liu1, Xianlong Ye1, Deshan Li3,4, Guiping Ren5.   

Abstract

PURPOSE: In this study, we explored whether treatment with FGF-21 could prevent diethylnitrosamine (DEN) induced hepatocarcinogenesis in mice. METHODS &
RESULTS: Hepatoma was induced by injection of DEN every three days for 18 weeks. For the prophylactic experiment, mice were firstly injected with FGF-21 for 2 weeks, then FGF-21 was administered to the mice once daily in association with DEN injection till the end of the experiment. The hepatoma incidence of mice treated with FGF-21 was 13.3%, while the incidence of mice treated with saline was 61.5%. To understand the mechanisms, we compared the expression of βklotho (KLB) and oxidative stress level in the livers between the mice treated with FGF-21 and saline. We found that FGF-21 could suppress DEN-induced oxidative stress and up-regulate the expression of KLB in the livers. To confirm these results, we compared the expression of KLB in L02 cells stimulated with or without FGF-21. Besides, we established DEN-induced oxidative stress cell model to affirm the relationship between FGF-21 and DEN-induced oxidative stress in vitro. Results showed that FGF-21 increased the expression of KLB and diminished the DEN-induced oxidative stress in vitro in a dose dependent manner.
CONCLUSION: Systemic administration of FGF-21 can prevent DEN-induced hepatocarcinogenesis via suppressing oxidative stress and increasing the expression of KLB.

Entities:  

Keywords:  Diethylnitrosamine; FGF-21; Hepatoma; Oxidative stress; βklotho

Mesh:

Substances:

Year:  2015        PMID: 26003555     DOI: 10.1007/s10620-015-3711-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  50 in total

1.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 2.  Liver: An organ with predominant innate immunity.

Authors:  Bin Gao; Won-Il Jeong; Zhigang Tian
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

3.  Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia-reperfusion injury.

Authors:  Wei-Tao Cong; Jin Ling; Hai-Shan Tian; Ren Ling; Yang Wang; Bin-Bin Huang; Ting Zhao; Yuan-Meng Duan; Li-Tai Jin; Xiao Kun Li
Journal:  Can J Physiol Pharmacol       Date:  2013-06-25       Impact factor: 2.273

4.  High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes.

Authors:  A Enomoto; K Itoh; E Nagayoshi; J Haruta; T Kimura; T O'Connor; T Harada; M Yamamoto
Journal:  Toxicol Sci       Date:  2001-01       Impact factor: 4.849

5.  Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein.

Authors:  S Ito; S Kinoshita; N Shiraishi; S Nakagawa; S Sekine; T Fujimori; Y I Nabeshima
Journal:  Mech Dev       Date:  2000-11       Impact factor: 1.882

6.  Effect of blueberry pretreatment on diethylnitrosamine-induced oxidative stress and liver injury in rats.

Authors:  İlknur Bingül; Canan Başaran-Küçükgergin; Merva Soluk Tekkeşin; Vakur Olgaç; Semra Doğru-Abbasoğlu; Müjdat Uysal
Journal:  Environ Toxicol Pharmacol       Date:  2013-06-10       Impact factor: 4.860

7.  Liver-specific activities of FGF19 require Klotho beta.

Authors:  Benjamin C Lin; Manping Wang; Craig Blackmore; Luc R Desnoyers
Journal:  J Biol Chem       Date:  2007-07-11       Impact factor: 5.157

Review 8.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

Authors:  Hashem B El-Serag; Howard Hampel; Fariba Javadi
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

Review 9.  Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.

Authors:  Monica Marra; Ignazio M Sordelli; Angela Lombardi; Monica Lamberti; Luciano Tarantino; Aldo Giudice; Paola Stiuso; Alberto Abbruzzese; Rossella Sperlongano; Marina Accardo; Massimo Agresti; Michele Caraglia; Pasquale Sperlongano
Journal:  J Transl Med       Date:  2011-10-10       Impact factor: 5.531

10.  Antioxidant N-acetylcysteine attenuates hepatocarcinogenesis by inhibiting ROS/ER stress in TLR2 deficient mouse.

Authors:  Heng Lin; Xiao-bo Liu; Jiao-jiao Yu; Fang Hua; Zhuo-wei Hu
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more
  8 in total

1.  FGF21 is induced in cisplatin nephrotoxicity to protect against kidney tubular cell injury.

Authors:  Fanghua Li; Zhiwen Liu; Chengyuan Tang; Juan Cai; Zheng Dong
Journal:  FASEB J       Date:  2018-01-22       Impact factor: 5.191

2.  Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy.

Authors:  Goo-Young Kim; Joon Hyun Kwon; Jun-Ho Cho; Lisa Zhang; Brian C Mansfield; Janice Y Chou
Journal:  Hum Mol Genet       Date:  2017-05-15       Impact factor: 6.150

3.  FGF21 ameliorates hepatic fibrosis by multiple mechanisms.

Authors:  Fanrui Meng; Mir Hassan Khoso; Kai Kang; Qi He; Yukai Cao; Xinghao Jiang; Wei Xiao; Deshan Li
Journal:  Mol Biol Rep       Date:  2021-09-18       Impact factor: 2.316

4.  Insulin sensitizes FGF21 in glucose and lipid metabolisms via activating common AKT pathway.

Authors:  Dan Yu; Xianlong Ye; Qiang Wu; Shujie Li; Yongbi Yang; Jinjiao He; Yunye Liu; Xiaoyu Zhang; Qingyan Yuan; Mingyao Liu; Deshan Li; Guiping Ren
Journal:  Endocrine       Date:  2015-11-25       Impact factor: 3.633

5.  FGF21 gene therapy as treatment for obesity and insulin resistance.

Authors:  Veronica Jimenez; Claudia Jambrina; Estefania Casana; Victor Sacristan; Sergio Muñoz; Sara Darriba; Jordi Rodó; Cristina Mallol; Miquel Garcia; Xavier León; Sara Marcó; Albert Ribera; Ivet Elias; Alba Casellas; Ignasi Grass; Gemma Elias; Tura Ferré; Sandra Motas; Sylvie Franckhauser; Francisca Mulero; Marc Navarro; Virginia Haurigot; Jesus Ruberte; Fatima Bosch
Journal:  EMBO Mol Med       Date:  2018-08       Impact factor: 12.137

Review 6.  Cellular Stresses and Stress Responses in the Pathogenesis of Insulin Resistance.

Authors:  Arnold N Onyango
Journal:  Oxid Med Cell Longev       Date:  2018-07-09       Impact factor: 6.543

Review 7.  Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers.

Authors:  Yue Sui; Jianping Chen
Journal:  Int J Biol Sci       Date:  2022-10-03       Impact factor: 10.750

8.  Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma.

Authors:  Takumi Kawaguchi; Sachiyo Yoshio; Yuzuru Sakamoto; Ryuki Hashida; Shunji Koya; Keisuke Hirota; Dan Nakano; Sakura Yamamura; Takashi Niizeki; Hiroo Matsuse; Takuji Torimura
Journal:  J Clin Med       Date:  2020-03-28       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.